Neovascular Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Neovascular Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial evaluating the efficacy and safety of ONS-5010 in neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders [Phase 3]
A 3-month Phase 3 safety study of ONS-5010 in subjects with visual impairment due to retinal disorders has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 clinical effectiveness study of ONS-5010 for neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I) [EARLY_Phase 1]
Investigator-initiated Phase 1 trial evaluating a CRISPR/cas13-mediated RNA targeting therapy for neovascular age-related macular degenerati…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD [Phase 3]
Phase 3 trial evaluating the efficacy and safety of IBI302 in neovascular age-related macular degeneration; the study is currently not recru…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration [Phase 1]
A Phase 1 trial evaluating ARC1905 in combination with Lucentis for neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) [Phase 1]
Phase 1 clinical trial update for AIV007 delivered periocularly in patients with macular edema due to Neovascular Age-Related Macular Degene…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. [Phase 4]
Phase 4 trial update evaluating multimodal imaging biomarkers to predict anatomical outcomes in naive patients with neovascular age-related …
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD) [NA]
This LMU project will evaluate whether an AI second-opinion report used to analyze retinal scans influences doctors' treatment decisions for…
-
CLINICAL_TRIALS research · 2025-02-03Clinical Trial Update: Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD
A study update examining recurrence and predictive OCT biomarkers in quiescent neovascular age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration [Phase 4]
Phase 4 trial evaluating two different 6 mg dosing regimens of brolucizumab for neovascular age-related macular degeneration, reporting on e…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Regulatory Post-Marketing Surveillance Study for Brolucizumab
Regulatory post-marketing surveillance clinical trial for brolucizumab is recruiting to monitor safety in neovascular age-related macular de…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
A terminated real-world trial evaluating the effectiveness of brolucizumab in pre-treated patients with neovascular age-related macular dege…
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating intravitreal SKG0106 for neovascular age-related macular degeneration is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1]
A Phase 1 clinical study evaluating the safety and efficacy of SKG0106 for neovascular age-related macular degeneration is currently recruit…
-
CLINICAL_TRIALS other · 2025-01-07Clinical Trial Update: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration [Phase 3]
Phase 3 clinical trial update comparing TAB014 to Lucentis for neovascular age-related macular degeneration; the study is active but not rec…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO [Phase 2]
Phase 2 study evaluating the usability of the SB11 prefilled syringe in subjects with wet age-related macular degeneration or macular edema …
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration [Phase 1]
A Phase 1 trial evaluating intravitreally administered AIV007 in neovascular age-related macular degeneration has completed. The update note…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Safety and Efficacy of AM712 in Patients with NAMD [Phase 1]
This update reports Phase 1 safety and preliminary efficacy results for AM712 in patients with Neovascular Age-related Macular Degeneration.
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) [Phase 4]
This Phase 4 trial evaluated the safety and effectiveness of intravitreal injections of brolucizumab for neovascular age-related macular deg…
-
CLINICAL_TRIALS trial_result · 2024-12-09Clinical Trial Update: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration [Phase 3]
Phase 3 study comparing the efficacy and safety of brolucizumab versus aflibercept in Chinese patients with Neovascular Age-Related Macular …
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Targeted Fluorescence Imaging in AMD [Phase 1]
Phase 1 clinical trial update on a targeted fluorescence imaging approach for age-related macular degeneration; the study has completed.
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]
This clinical trial update reports on the safety and tolerability assessment of KH658 gene therapy in subjects with neovascular age-related …
-
CLINICAL_TRIALS trial_result · 2024-11-27Clinical Trial Update: Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]
Phase 1/2 clinical trial update on KH631 gene therapy for neovascular age-related macular degeneration, focusing on safety and tolerability;…
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
A clinical trial investigating aflibercept 8 mg for neovascular age-related macular degeneration and diabetic macular edema in real-world se…